We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients.
- Abstract
The article highlights the results of a study which suggest that the appearance of a rash in cancer patients treated with erlotinib (Tarceva) is strongly associated with longer survival. The study was conducted by researchers from the drug's developer, OSI Pharmaceuticals Inc. The article reports that for patients taking erlotinib who developed a moderate to severe rash, survival without progression of disease was 245 percent longer than in patients who had a mild rash or none at all.
- Subjects
CANCER treatment; DRUG side effects; SKIN diseases; OSI Pharmaceuticals Inc.; LUNG cancer; PANCREATIC cancer
- Publication
Oncology (08909091), 2007, Vol 21, Issue 9, p1080
- ISSN
0890-9091
- Publication type
Article